Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in recurrent/metastatic nasopharyngeal carcinoma
NCT06839066Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HLX43 in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Henlius. Primary endpoints: Objective Response Rate at 24 weeks and Progression-Free Survival at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06839066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839066.